Lymph-node metastases in patients with melanoma: what is the optimum management?
Authors:
- 1 October 2001
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 2 (10) , 614-621
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801Journal of Clinical Oncology, 2001
- Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Recurrence Patterns and Outcome in 1019 Patients Undergoing Axillary or Inguinal Lymphadenectomy for MelanomaArchives of Surgery, 1992
- Loco-regional nodal relapse in melanomaSurgical Oncology, 1992
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992
- Experience with 998 cutaneous melanomas of the head and neck over 30 yearsThe American Journal of Surgery, 1991
- Axillary node dissection in malignant melanomaThe American Journal of Surgery, 1991
- Patterns of Relapse in 1001 Consecutive Patients With Melanoma Nodal MetastasesArchives of Surgery, 1989
- Morbidity, mortality and local recurrence following regional node dissection for melanomaBritish Journal of Surgery, 1986